CellAura combines world-renowned expertise from the University of Nottingham in the areas of man made chemistry and molecular pharmacology to produce top quality fluorescent receptor ligands as essential components in drug applicant screening assays and imaging techniques. This fresh partnership with Cisbio Bioassays, which is one of the leaders in bioassays for cell surface area receptor and functional studies, recognizes our rapid progress and is a major milestone. To enhance our Tag-lite platform addressing this area, we seek out partnerships with the very best experts in their respective fields, and so are very happy to collaborate with CellAura for the development of nonradioactive fluorescent ligands.?.. CellAura to provide pharmacologically validated reagents for Cisbio Bioassays’ cellular studies CellAura, the leading maker of fluorescence reagents for drug existence and discovery sciences analysis, announced a advancement partnership with Cisbio Bioassays today.AstraZeneca enters agreement with Pfizer for OTC NEXIUM Pfizer Inc. today announced that it provides entered into an contract with AstraZeneca for the over-the-counter privileges for NEXIUM , a respected prescription drug currently approved to deal with the outward symptoms of gastroesophageal reflux disease . Under the conditions of the contract, Pfizer shall acquire the exclusive global privileges to advertise NEXIUM for the accepted over-the-counter indications in the usa, Europe and the others of the world. Beneath the agreement, Pfizer can make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is definitely eligible to receive royalty and milestone obligations predicated on product launches and product sales.